Abstract
The most abundant microRNA (miRNA) in the liver, miR-122, is regulated by specific, liver-enriched transcription factors and is responsible for proper proliferation and differentiation of hepatocytes and for the regulation of lipid and cholesterol metabolisms. miR-122 is also involved in several hepatic disorders, as downregulation of miR-122 is often associated with hepatocellular carcinoma (HCC) and miR-122 is a required component for the replication and proliferation of the hepatitis C virus (HCV). Various probes have been developed to promote a better understanding of the involvement of miR-122 in liver diseases, including modified antisense agents and small molecule inhibitors. These agents, capable of specifically modifying miR-122 activity, provide excellent tools to investigate the function and regulation of miR-122 and offer potential new lead compounds for drug discovery. Especially small molecule modifiers can display numerous advantages over nucleotide analogs, as discussed in this review.
Keywords: miRNA-122, liver disorders, miRNA therapeutics, small molecules, antisense oligonucleotides, antagomirs, hepatitis C virus, hepatocellular carcinoma, lipid and cholesterol metabolism, regulation of miRNA function.
Current Medicinal Chemistry
Title:MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules
Volume: 20 Issue: 29
Author(s): M. Thomas and A. Deiters
Affiliation:
Keywords: miRNA-122, liver disorders, miRNA therapeutics, small molecules, antisense oligonucleotides, antagomirs, hepatitis C virus, hepatocellular carcinoma, lipid and cholesterol metabolism, regulation of miRNA function.
Abstract: The most abundant microRNA (miRNA) in the liver, miR-122, is regulated by specific, liver-enriched transcription factors and is responsible for proper proliferation and differentiation of hepatocytes and for the regulation of lipid and cholesterol metabolisms. miR-122 is also involved in several hepatic disorders, as downregulation of miR-122 is often associated with hepatocellular carcinoma (HCC) and miR-122 is a required component for the replication and proliferation of the hepatitis C virus (HCV). Various probes have been developed to promote a better understanding of the involvement of miR-122 in liver diseases, including modified antisense agents and small molecule inhibitors. These agents, capable of specifically modifying miR-122 activity, provide excellent tools to investigate the function and regulation of miR-122 and offer potential new lead compounds for drug discovery. Especially small molecule modifiers can display numerous advantages over nucleotide analogs, as discussed in this review.
Export Options
About this article
Cite this article as:
Thomas M. and Deiters A., MicroRNA miR-122 as a Therapeutic Target for Oligonucleotides and Small Molecules, Current Medicinal Chemistry 2013; 20 (29) . https://dx.doi.org/10.2174/0929867311320290009
DOI https://dx.doi.org/10.2174/0929867311320290009 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Toll-Like Receptors in Human Multiple Myeloma: New Insight into Inflammation-Related Pathogenesis
Current Molecular Medicine Oncoproteomics of Neuroblastoma: A Blueprint for Future Progress
Current Proteomics The Impact of Thrombopoietin on Clinical Practice
Current Pharmaceutical Design MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer
Current Cancer Drug Targets Novel 3-(1-acetyl-5-(substituted-phenyl)-4,5-dihydro-1H-pyrazol-3-yl)-7-fluoro-2H-chromen-2-one Derivatives: Synthesis and Anticancer Activity
Letters in Drug Design & Discovery Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
Current Medicinal Chemistry RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Current Medicinal Chemistry Selective Toxicity of Apigenin on Cancerous Hepatocytes by Directly Targeting their Mitochondria
Anti-Cancer Agents in Medicinal Chemistry PET Imaging for Gene & Cell Therapy
Current Gene Therapy Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Drug Carriers in Pharmaceutical Design: Promises and Progress
Current Pharmaceutical Design Development of Fourth Generation ABC Inhibitors from Natural Products: A Novel Approach to Overcome Cancer Multidrug Resistance
Anti-Cancer Agents in Medicinal Chemistry Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis
Current Drug Targets Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Biomarkers and Multiple Drug Resistance in Breast Cancer
Current Cancer Drug Targets Molecular Targets and Targeted Therapies for Malignant Mesothelioma
Current Medicinal Chemistry Genes Associated with Epithelial-Mesenchymal Transition: Possible Therapeutic Targets in Ductal Pancreatic Adenocarcinoma?
Anti-Cancer Agents in Medicinal Chemistry